RESMETIROM
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $1.7M | 13,832 | 7,511 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 144 | 75.5% |
| Food and Beverage | $370,657 | 13,659 | 21.9% |
| Honoraria | $43,445 | 24 | 2.6% |
| Travel and Lodging | $1,651 | 5 | 0.1% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | Madrigal Pharmaceuticals | $1.3M | 0 |
Top Doctors Receiving Payments for RESMETIROM — Page 4
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , NP | Registered Nurse | New York, NY | $292.54 | 5 |
| , MD | Gastroenterology | Long Beach, CA | $292.12 | 6 |
| , M.D | Gastroenterology | Parker, CO | $278.70 | 4 |
| , PHYSICIAN ASSISTANT | Physician Assistant | Las Vegas, NV | $278.64 | 8 |
| , M.D | Specialist | Paramount, CA | $275.52 | 10 |
| , FNP-C | Family Medicine | Phoenix, AZ | $271.10 | 5 |
| , DNP | Family | San Antonio, TX | $270.76 | 3 |
| , MD | Transplant Hepatology | Burlington, MA | $270.14 | 2 |
| , NP-C | Family | Flowood, MS | $269.36 | 5 |
| , PA-C | Physician Assistant | Indianapolis, IN | $268.16 | 10 |
| Raul Caldera | Nurse Practitioner | Norwalk, CA | $266.37 | 21 |
| , M.D | Gastroenterology | Hato Rey, PR | $265.64 | 4 |
| , M.D | Gastroenterology | Wynnewood, PA | $263.12 | 7 |
| , M.D | Internal Medicine | Los Angeles, CA | $260.79 | 2 |
| Melissa Real | Physician Assistant | Pasadena, CA | $260.34 | 9 |
| Rachel Morales | Student in an Organized Health Care Education/Training Program | Fort Lauderdale, FL | $260.04 | 2 |
| , M.D | Gastroenterology | Bradenton, FL | $258.24 | 4 |
| , MD | Internal Medicine | Newark, NJ | $255.64 | 7 |
| Cher Diaz | Family | Miami Beach, FL | $255.62 | 4 |
| , DO | Gastroenterology | Yuba City, CA | $253.08 | 11 |
| , M.D | Hepatology | Coronado, CA | $253.04 | 2 |
| , D.O | Internal Medicine | San Diego, CA | $251.89 | 4 |
| , FNP | Family | Dallas, TX | $251.44 | 4 |
| , NP | Acute Care | Los Angeles, CA | $250.25 | 3 |
| , M.D | Internal Medicine | Loma Linda, CA | $249.47 | 2 |
Manufacturing Companies
- Madrigal Pharmaceuticals $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 7,511
- Transactions 13,832
About RESMETIROM
RESMETIROM is a drug associated with $1.7M in payments to 7,511 healthcare providers, recorded across 13,832 transactions in the CMS Open Payments database. The primary manufacturer is Madrigal Pharmaceuticals.
Payment data is available from 2024 to 2024. In 2024, $1.7M was paid across 13,832 transactions to 7,511 doctors.
The most common payment nature for RESMETIROM is "Unspecified" ($1.3M, 75.5% of total).
RESMETIROM is associated with 1 research study, including "A 52-Week, Phase 3, Open-Label Extension Study, With a Double-blind Lead-in, to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)" ($1.3M).